CHMP Recommends Enbrel Biosimilar Nepexto for Approval in Europe
The Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Nepexto, a biosimilar of Enbrel (etanercept), for the treatment ... Read more
Updates
-
-
NORD Partners with ‘Sing Me a Story’ for July 18–20 Living Rare Forum
The Living Rare, Living Stronger Patient and Family Forum, originally set for May 14–16 in Cleveland, Ohio, has been postponed until July 18–20 because ... Read more -
Kicking Alcohol Changed My Ankylosing Spondylitis Experience
After my diagnosis of ankylosing spondylitis (AS) in 2017, my doctor told me to quit drinking and smoking and to start a decent ... Read more -
Global Rare Disease Group’s Focus: 1,000 New Therapies by 2027, Despite COVID-19
Even with the coronavirus pandemic ravaging Europe and much of the world, patient advocate Lucia Monaco, PhD, of Italy remains confident that the Paris-based ... Read more
Subscribe to our mailing list
Get regular updates delivered to your email box.
Thanks! Please check your email for a confirmation email.
-
Balance Your Anxiety and Concern About COVID-19
I’ve noticed lately that public health crises, such as the new coronavirus pandemic, make ... -
2nd Humira Biosimilar Seen as Effective and Safe in Phase 3 Trial in China
HS016, a biosimilar candidate of Humira (adalimumab), was seen to have equivalent safety and effectiveness at ... -
Everything You’ve Ever Wanted to Know About AS
Look, I get it. You can’t blame people for being curious. It’s hard not ... -
Pediatric Rare Disease Therapies Increase, But Most Repurposed, Study Finds
The number of treatments for children with rare diseases has grown over the past decade, ... -
TNF Blockers Show Real-life Benefits in Patients, Study Finds
Treatment with TNF inhibitors eased disease activity and improved physical function for people with ...
Cosentyx Leads to Long-Term Improvement in AS Patients, Phase 3 Trial Shows
News
Results from a Phase 3 clinical trial show that treatment with Cosentyx (secukinumab) led to fast, significant, and sustained symptom improvement in patients with active ankylosing spondylitis (AS). Improvements were particularly noticeable in patients who had never ... Read more